Hansa Biopharma, a company involved in immunomodulatory enzyme technology for rare IgG mediated diseases, has named Professor Achim Kaufhold as its new chief medical officer, it was reported on Friday.
Kaufhold has served as CMO and member of the Executive Committee at Basilea Pharmaceutica in Switzerland. He is a senior pharmaceutical executive within immunology, infectious diseases and oncology.
Soren Tulstrup, president and CEO, Hansa Biopharma, said, 'I am very happy that we have managed to attract Achim Kaufhold as CMO. 2020 promises to be a transformative year for our company with the potential EU regulatory approval of imlifidase in kidney transplantation and top line data from the first phase 2 trial in autoimmune diseases.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer